Companion Pharmacogenetic Study to UMCC 9900/9901

U

University of Michigan Rogel Cancer Center

Status

Terminated

Conditions

Metastatic Breast Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT00146029
UMCC 3-27

Details and patient eligibility

About

The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who participated on UMCC 9900/9901
  • Living patients must give written informed consent

Exclusion criteria

No tumor block tissue available

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems